CALZF (Polynovo) ROE % Adjusted to Book Value : 0.59% (As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is Polynovo ROE % Adjusted to Book Value?

Polynovo's ROE % for the quarter that ended in Dec. 2024 was 8.84%. Polynovo's PB Ratio for the quarter that ended in Dec. 2024 was 15.07. Polynovo's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was 0.59%.

Polynovo ROE % Adjusted to Book Value Historical Data

The historical data trend for Polynovo's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Polynovo ROE % Adjusted to Book Value Chart

Polynovo Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-0.22

-0.27

-0.11

-0.56

0.31

Polynovo Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-1.01	-0.16	0.67	0.30	0.59

Competitive Comparison of Polynovo's ROE % Adjusted to Book Value

For the Medical Devices subindustry, Polynovo's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Polynovo's ROE % Adjusted to Book Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Polynovo's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Polynovo's ROE % Adjusted to Book Value falls into.

Polynovo ROE % Adjusted to Book Value Calculation

Polynovo's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	7.61%	/	24.35
	=	0.31%

Polynovo's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	8.84%	/	15.07
	=	0.59%

Polynovo ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Polynovo's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Polynovo Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Polynovo Ltd (OTCPK:CALZF) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

MFJ:Germany PNV:Australia

Address

320 Lorimer Street, Unit 2, Port Melbourne, VIC, AUS, 3207

Website

https://www.polynovo.com

Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.